Page 1
AGENDA Day 1
4:00 Arrival & Registration (Napa Meeting Foyer)
6:00 Biotech CEO Summit Welcome Reception (The Carneros Courtyard)
6:30 Opening Remarks and Introductions
• Sara Jane Demy , CEO, Demy-Colton
7:00 Fireside Chat – The Purposeful CEO – Building a biotech company that makes a difference
• Interviewee: Rich Heyman, Executive Chairman & Co-Founder, Metacrine Inc.; former CEOof Seragon & Aragon
• Interviewer: Mark Simon, Partner & Co-Founder, Torreya
7:45 Networking Dinner Reception (Sonoma Meeting Hall)
Day 2
7:00 Breakfast (FARM Dining Room)
8:15 Overview and Rules of Engagement (Napa Meeting Hall)
• Sara Jane Demy, CEO & Founder, Demy-Colton
8:30 DISCUSSION 1: Setting the Strategic Direction—Are the Best Opportunities Aligned to Your “Reason for Being”?
Discussants: • Ben Bonifant (Leader), Founder, Triangle Insights Group• Bill Newell, CEO, Sutro Biopharma• Bassil Dahiyat, President and CEO, Xencor, Inc.• Susan Molineaux, CEO, Calithera Biosciences
Page 2
11:15 DISCUSSION 3: Planning for approval and commercialization early in the development process—Which steps are necessary and which are a waste of time and money?
Discussants: • Chris Apolito (Leader), Chris Apolito, Partner, Triangle Insights Group• Kathleen Sanzo, Partner, Morgan, Lewis & Bockius LLP• Ted Haack, Vice President, LatticePoint Consulting• Jeffrey Bergau, Jeffrey Bergau, Founding Partner, CG Life
12:15 Networking Lunch (FARM Patio)
1:15 DISCUSSION 4: Maximizing returns – How do you balance your shareholder’s needs, patient access, perception of your company and perception of the industry?
Discussants: • Chris Ehrlich (Leader), Chris Ehrlich, Managing Director, Locust Walk• Ben Pensak, Ben Pensak, Partner, Morgan, Lewis & Bockius LLP• Ted Haack, Vice President, LatticePoint Consulting• Susan Molineaux, Susan Molineaux, CEO, Calithera Biosciences
2:15 DISCUSSION 5: Money – Which of the different flavors of capital for public and private companies is best for you? (Break out into two groups)
Private discussion (Group 1): • Jennifer Friel Goldstein, Market Manager,
Head of West Coast, Life Science & Healthcare and Accelerator, Silicon Valley Bank
• Chris Ehrlich, Managing Director, Locust Walk• Jeff Cleland, President and CEO, GrayBug
Vision, Inc.• Kimberly Ha, Senior Director, Strategic
Communications, FTI Consulting• Michael O’Donnell, Partner, Morrison &
Foerster LLP
9:45 Morning Break
10:15 DISCUSSION 2: Strategic Direction and The Board—When and how do you engage them in strategic discussions?
Discussants: • Mark Kessel (Leader), Of Counsel, Shearman & Sterling LLP• Julia Gregory, CEO, Isometry Advisors, Inc.• Jeff Cleland, President and CEO, GrayBug Vision, Inc.• Gaylene Xanthopoulos, President & Founder, The Leadership Edge• Christos Richards, Partner, Catalyst Advisors, LP
Public discussion (Group 2): • KC Stone, Managing Director, Head of
Healthcare Investment Banking, BTIG, LLC• Dave Sabow, Head of Life Sciences, Client
Funds & Products, Silicon Valley Bank• Julia Gregory, CEO & Chairman, Isometry
Advisors, Inc.• Bassil Dahiyat, President and CEO, Xencor,
Inc.
Page 3
Day 3
7:00 Breakfast (FARM Dining Room)
8:00 DISCUSSION 6: Communications strategy—What is the right story for your company and is the answer different depending on the audience? (Napa Meeting Hall)
Discussants: • Jeffrey Bergau (Leader), Founding Partner, CG Life• Jeff Cleland, President and CEO, GrayBug Vision, Inc.• Michael McCully, Vice President, Locust Walk Partners• Kimberly Ha, Senior Director, Strategic Communications, FTI Consulting
9:00 DISCUSSION 7: Leading through adversity; it happens to every biotech CEO—Whom should you consult for guidance, and how should you prioritize your response?
Discussants: • Ben Bonifant (leader), Founder, Triangle Insights Group• Mark Kessel, Of Counsel, Shearman & Sterling LLP• Basil Dahiyat, President and CEO, Xencor, Inc.• Mark Simon, Partner and Co-Founder, Torreya
10:30 DISCUSSION 8: Team development—Does the company’s early team have the diversity of backgrounds and perspectives for later success?
Discussants: • Robin Toft (Leader), President & CEO, Toft Group Executive Search• Julia Gregory, CEO & Chairman, Isometry Advisors, Inc.• Gaylene Xanthopoulos, President & Founder, The Leadership Edge• Rich Ramko, Life Sciences Assurance Leader, West Region, Ernst & Young
4:15 BIOTECH CEO SUMMIT GAMES (The Carneros Courtyard)
6:30 WINE TASTING AND GALA DINNER AND AWARDS (Hilltop Dining Room & Patios)
3:15 Afternoon Break
3:30 An unguarded conversation among CEOs & Friends–Embracing change
• Interviewee: Cindy Collins, CEO, Human Longevity, Inc.
• Interviewer: Christos Richards, Partner, Catalyst Advisors, LP
Page 4
3:30 AN UNGUARDED CONVERSATION AMONG CEOS AND FRIENDS—The characteristics of a successful biotech CEO
Discussants: • Gaylene Xanthopoulos (Leader), President & Founder, The Leadership Edge• Julia Gregory, CEO & Chairman, Isometry Advisors, Inc.• Robin Toft, President & CEO, Toft Group Executive Search• Rich Heyman, Executive Chairman & Co-Founder, Metacrine Inc.; former CEO of Seragon
& Aragon
4:30 CLOSING RECEPTION (The Carneros Courtyard)
2:30 DISCUSSION 11: Critical inflection points—How have you survived the make or break moments that led to success?
Discussants: • Jennifer Friel Goldstein (Leader),• Bill Newell, CEO, Sutro Biopharma• Bassil Dahiyat, President and CEO, Xencor, Inc.• Susan Molineaux, CEO, Calithera Biosciences
12:30 Lunch (FARM Patio)
1:30 DISCUSSION 10: Administrative change and the CEOs responsibilities—Policy changes can shake-up the landscape beyond imagination; when do you need to go beyond just staying informed?
Discussants: • Kathleen Sanzo (Leader), Partner, Morgan, Lewis & Bockius LLP• Ted Haack, Vice President, LatticePoint Consulting• Rich Ramko, Life Sciences Assurance Leader, West Region, Ernst & Young
11:30 DISCUSSION 9: Board development—How do you prod your board toward adapting to new realities and get them in alignment with your vision?
•Discussants:
•Christos Richards (Leader), Partner, Catalyst Advisors, LP
•Bill Newell, CEO, Sutro Biopharma
•
Rich Heyman, Executive Chairman & Co-Founder, Metacrine Inc.; former CEO of Seragon & Aragon
•Cindy Collins, CEO, Human Longevity, Inc.Michael O’ Donnell, Partner, Morrison & Foerster LLP